Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28547076 | 0.81 | DYRK1A (0.33) | DYRK1ACYP3A4 | |
| SCHEMBL8058607 | 0.78 | DYRK1A (0.49) | DYRK1ACYP3A4ALDH1A1LMNACYP1A2 | |
| SCHEMBL249194 | 0.78 | DYRK1A (0.38) | DYRK1ACYP3A4ALDH1A1LMNACYP1A2 | |
| SCHEMBL28540640 | 0.73 | DYRK1A (0.37) | DYRK1ACYP3A4 | |
| SCHEMBL28537969 | 0.73 | DYRK1A (0.37) | DYRK1ACYP3A4ALDH1A1LMNACYP1A2 | |
| SCHEMBL313794 | 0.71 | — | — | |
| SCHEMBL3417389 | 0.67 | NPC1 (0.40) | ALDH1A1MAPTSMN1; SMN2NPSR1GPR55 | |
| SCHEMBL249195 | 0.64 | DYRK1A (0.45) | DYRK1ACYP3A4ALDH1A1LMNACYP1A2 | |
| SCHEMBL7199150 | 0.63 | ACHE (0.61) | CYP3A4ALDH1A1LMNACYP1A2CYP2D6 | |
| SCHEMBL8884724 | 0.63 | KDM4E (0.41) | ALDH1A1LMNACYP1A2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140933-A1 | CAMPTOTHECIN DERIVATIVE, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD AND USE THEREFOR | 长春金赛药业有限责任公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024104452-A1 | MC4R ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL USE THEREOF | 长春金赛药业有限责任公司 | 2024-05-23 | — | — | WO | disclosed |
| WO-2024067675-A1 | FUSED RING KIF18A INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024061357-A1 | HARRINGTONINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 南开大学 | 2024-03-28 | — | — | WO | disclosed |
| WO-2024051755-A1 | KIF18A INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-14 | — | — | WO | disclosed |
| WO-2024046327-A1 | P38α-MK2 INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 长春金赛药业有限责任公司 | 2024-03-07 | — | — | WO | disclosed |
| CN-111747950-B | Pyrimidine derivatives for the treatment of cancer | 深圳福沃药业有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | NOVARTIS AG (CH) | 2024-01-11 | — | — | US | disclosed |
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SUZHOU YABAO PHARMACEUTICAL R&D CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | disclosed |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | BRATTON LARRY D (US) | 2004-10-21 | — | — | US | disclosed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6716842-B2 | NON-INSULIN DEPENDENT DIABETES MELLITUS, OBESITY, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEREMIA, ATHEROSCLEROSIS, HYPERTRIGLYCERIDEMIA, HYPERINSULINEMIA IN A MAMMAL | WARNER-LAMBERT COMPANY, LLC | 2004-04-06 | — | — | US | disclosed |
| US-6696474-B2 | SUCH AS 8-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-2-PYRROL-1-YL-OCT-4-YNOIC ACID; NONINSULIN DEPENDENT DIABETES MELLITUS | WARNER LAMBERT CO. LLC. | 2004-02-24 | — | — | US | disclosed |
| US-20030225083-A1 | Antidiabetic agents | FAKHOURY STEPHEN A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY, LLC | 2003-11-27 | — | — | US | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2003-08-28 | — | — | US | disclosed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | DYRK1A 1432/4885CYP3A4 309/4885ALDH1A1 874/4885 |
| US-20030220381-A1 | ANTIDIABETIC AGENTS | GPR119, GCKR, GLP1R | DYRK1A 2690/4885CYP3A4 622/4885ALDH1A1 1434/4885 |
| US-20240009189-A1 | 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS | SMN1; SMN2, CLN6, PMP22 | DYRK1A 3148/4885CYP3A4 3653/4885ALDH1A1 741/4885 |
| US-20030162787-A1 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | TFPI, F11, F12 | DYRK1A 4675/4885CYP3A4 1036/4885ALDH1A1 2068/4885 |
| US-20040209936-A1 | Compounds that modulate PPAR activity and methods of preparation | PPARA, PPARG, PPARD | DYRK1A 3920/4885CYP3A4 1257/4885ALDH1A1 1771/4885 |
| US-20230391775-A1 | SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | LRRK2, COMT, PARK7 | DYRK1A 115/4885CYP3A4 1254/4885ALDH1A1 1791/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | DYRK1A 3130/4885CYP3A4 3584/4885ALDH1A1 2456/4885 |
| US-20030225083-A1 | Antidiabetic agents | GPR119, IAPP, SLC5A1 | DYRK1A 3316/4885CYP3A4 195/4885ALDH1A1 416/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | DYRK1A 4493/4885CYP3A4 4599/4885ALDH1A1 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.